Rezolute, Inc. (NASDAQ:RZLT) CFO Purchases $41,400.00 in Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 9,000 shares of the stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $4.60 per share, for a total transaction of $41,400.00. Following the acquisition, the chief financial officer now directly owns 140,900 shares in the company, valued at approximately $648,140. This trade represents a 6.82 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rezolute Price Performance

NASDAQ:RZLT opened at $4.59 on Friday. The company has a market capitalization of $265.96 million, a price-to-earnings ratio of -3.61 and a beta of 1.01. The business has a 50 day moving average of $5.16 and a 200 day moving average of $4.77. Rezolute, Inc. has a 1-year low of $0.81 and a 1-year high of $6.19.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). As a group, sell-side analysts anticipate that Rezolute, Inc. will post -0.99 EPS for the current year.

Institutional Trading of Rezolute

Several institutional investors have recently added to or reduced their stakes in RZLT. Vanguard Group Inc. boosted its holdings in Rezolute by 10.4% during the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock valued at $3,961,000 after acquiring an additional 145,700 shares during the period. Cubist Systematic Strategies LLC boosted its stake in shares of Rezolute by 366.0% during the second quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares during the period. Marshall Wace LLP bought a new position in shares of Rezolute in the second quarter worth approximately $4,503,000. Affinity Asset Advisors LLC increased its stake in shares of Rezolute by 15.6% in the second quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock worth $7,955,000 after buying an additional 250,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Rezolute in the third quarter worth $239,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RZLT has been the topic of a number of recent research reports. JMP Securities reissued a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Rezolute in a report on Friday, November 8th. Guggenheim initiated coverage on Rezolute in a research note on Tuesday, August 27th. They set a “buy” rating and a $11.00 price objective for the company. BTIG Research lifted their target price on shares of Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Finally, Wedbush reissued an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a research note on Monday, November 4th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $24.13.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.